Variations in the use of an innovative technology by payer: the case of drug-eluting stents
- PMID: 22167062
- PMCID: PMC3240810
- DOI: 10.1097/MLR.0b013e31822d5de9
Variations in the use of an innovative technology by payer: the case of drug-eluting stents
Abstract
Background: Despite receiving identical reimbursement for treating heart disease patients with bare metal stents (BMS) or drug-eluting coronary stents (DES), cardiologists' use of the new technology (DES) may have varied by patient payer type as DES diffused. Payer-related factors that differ between hospitals and/or differential treatment inside hospitals might explain any overall differences by payer type.
Objectives: To assess the association between payer and DES use and to examine between-hospital and within-hospital variation in DES use over time.
Methods: We conducted a retrospective analysis of 4.1 million hospitalizations involving DES or BMS from 2003 to 2008 Nationwide Inpatient Sample. We estimated hybrid-fixed effects logit models and calculated the adjusted within-quarter, cross-payer differences in DES use.
Results: Coronary stent patients with Medicaid or without insurance were significantly less likely to receive DES than were patients with private insurance throughout the study period. The differences fluctuated over time as the popularity of DES relative to BMS increased and decreased. The within-hospital gaps paralleled the overall differences, and were largest in Q3 2003 (Medicaid: 11.9, uninsured: 10.9% points) and Q4 2008 (Medicaid: 12.8, uninsured: 20.7% points), and smallest in Q4 2004 (Medicaid: 1.4, uninsured: 1.1% points). The between-hospital adjusted differences in DES use by payer were small and rarely significant.
Conclusions: We found substantial differences in DES use by payer within hospitals, suggesting physicians selected the new technology for patients in a manner associated with patients' payer type.
Conflict of interest statement
None of the authors had any personal or financial conflicts of interest in regard to this study. The content of this article does not reflect the views of the VA or the US government.
Figures
Similar articles
-
Differences in utilization of drug-eluting stents by race and payer.Am J Cardiol. 2007 Oct 15;100(8):1192-8. doi: 10.1016/j.amjcard.2007.05.039. Epub 2007 Aug 2. Am J Cardiol. 2007. PMID: 17920356
-
African-American patients are less likely to receive drug-eluting stents during percutaneous coronary intervention.Cardiovasc Revasc Med. 2014 Jun;15(4):214-8. doi: 10.1016/j.carrev.2014.04.003. Epub 2014 Apr 12. Cardiovasc Revasc Med. 2014. PMID: 24814420
-
Primary payer status is associated with mortality and resource utilization for coronary artery bypass grafting.Circulation. 2012 Sep 11;126(11 Suppl 1):S132-9. doi: 10.1161/CIRCULATIONAHA.111.083782. Circulation. 2012. PMID: 22965973 Free PMC article.
-
The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.Cardiovasc Ther. 2015 Dec;33(6):360-6. doi: 10.1111/1755-5922.12160. Cardiovasc Ther. 2015. PMID: 26363283 Review.
-
Clinical Effectiveness and Cost Effectiveness of Intracoronary Brachytherapy and Drug Eluting Stents [Internet].Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2004. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 08-2004. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2004. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 08-2004. PMID: 29320006 Free Books & Documents. Review.
Cited by
-
Insights into measuring health disparities using electronic health records from a statewide network of health systems: A case study.J Clin Transl Sci. 2023 Feb 1;7(1):e54. doi: 10.1017/cts.2022.521. eCollection 2023. J Clin Transl Sci. 2023. PMID: 37008604 Free PMC article.
-
An Exploratory Analysis of Differential Prescribing of High-Risk Opioids by Insurance Type Among Patients Seen by the Same Clinician.J Gen Intern Med. 2023 May;38(7):1681-1688. doi: 10.1007/s11606-023-08025-6. Epub 2023 Feb 6. J Gen Intern Med. 2023. PMID: 36745303 Free PMC article.
-
Racial Disparities in Severe Maternal Morbidity in an Integrated Health Care System, Southern California, 2008-2017.Womens Health Issues. 2023 May-Jun;33(3):280-288. doi: 10.1016/j.whi.2023.01.001. Epub 2023 Feb 3. Womens Health Issues. 2023. PMID: 36740539 Free PMC article.
-
How real can we get in generating real world evidence? Exploring the opportunities of routinely collected administrative data for evaluation of medical devices.Health Econ. 2022 Sep;31 Suppl 1(Suppl 1):25-43. doi: 10.1002/hec.4562. Epub 2022 Jun 28. Health Econ. 2022. PMID: 35762465 Free PMC article.
-
Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States.Clin J Am Soc Nephrol. 2022 Jul;17(7):976-985. doi: 10.2215/CJN.00840122. Epub 2022 Jun 20. Clin J Am Soc Nephrol. 2022. PMID: 35725555 Free PMC article.
References
-
- Bodenheimer T. High and rising health care costs. Part 2: technological innovation. Ann Intern Med. 2005;142(11):932–937. - PubMed
-
- Hurley RE, Pham HH, Claxton G. A widening rift in access and quality: growing evidence of economic disparities. Health Aff. 2005;24:w566–w576. - PubMed
-
- Doyle JJ. Health insurance, treatment and outcomes: using auto accidents as health shocks. Rev Econ Stat. 2005;87(2):256–270.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
